INVESTABOT
Equity Research
XNYS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Zoetis grew Q1 2026 revenue 2.9% to $2.26B from $2.20B a year ago, while net income came in at $601 million, or $1.42 per diluted share.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/7/2026 | DAMELIO FRANK A | — | GIFT | -6,650 | — | — |
| 7/10/2026 | Joseph Wetteny | Chief Financial Officer | GRANT | 363.05 | $26 | $9,519 |
| 7/10/2026 | Ferran Astorga Jeannette | Executive Vice President | GRANT | 45.33 | $26 | $1,188 |
| 7/10/2026 | Lagano Roxanne | Executive Vice President | GRANT | 314.65 | $26 | $8,250 |
| 7/10/2026 | FULLER JULIE | Executive Vice President | GRANT | 314.65 | $26 | $8,250 |
| 7/10/2026 | Driscoll Rimma | Executive Vice President | GRANT | 237.64 | $26 | $6,231 |
| 7/10/2026 | Esch Kevin | Executive Vice President | GRANT | 308.05 | $26 | $8,077 |
| 7/10/2026 | Nayak Abhay U | Executive Vice President | GRANT | 214.62 | $26 | $5,627 |
| 7/10/2026 | PECK KRISTIN C | Chief Executive Officer | GRANT | 616.09 | $26 | $16,154 |
| 7/10/2026 | Sarbaugh Keith | Executive Vice President | GRANT | 259.64 | $26 | $6,808 |
| 6/18/2026 | Stetter Mark | — | GRANT | 317.62 | $79 | $25,000 |
| 6/10/2026 | MCCALLISTER MICHAEL B | — | GIFT | -1,209 | — | — |
| 5/21/2026 | Stetter Mark | — | OPTION_EXERCISE | -1,572.06 | — | — |
| 5/21/2026 | Stetter Mark | — | OPTION_EXERCISE | 1,572 | — | — |
| 5/20/2026 | PARENT LOUISE M | — | OPTION_EXERCISE | -10,186.67 | — | — |
| 5/20/2026 | PARENT LOUISE M | — | OPTION_EXERCISE | -1,944.36 | — | — |
| 5/20/2026 | PARENT LOUISE M | — | OPTION_EXERCISE | 10,186 | — | — |
| 5/20/2026 | PARENT LOUISE M | — | OPTION_EXERCISE | 1,944 | — | — |
| 5/13/2026 | Bisaro Paul | — | BUY | 2,000 | $76 | $151,750 |
| 5/13/2026 | DAMELIO FRANK A | — | BUY | 6,650 | $75 | $501,344 |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| 6/17/2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 36,835,040 | $6,385,722,454 | — | 8/13/2024 |
| Vanguard Group | 47,780,974 | $6,011,802,148 | — | 1/29/2026 |
| BlackRock | 37,350,823 | $4,699,480,504 | — | 2/12/2026 |
| BlackRock | 35,584,312 | $4,206,421,478 | -4.7% | 5/13/2026 |
| BlackRock | 39,430,181 | $2,833,452,809 | 10.8% | 8/7/2026 |
| State Street | 19,796,891 | $2,490,844,826 | — | 2/13/2026 |
| State Street | 19,324,401 | $2,284,337,442 | -2.4% | 5/15/2026 |
| Morgan Stanley | 15,465,506 | $1,945,870,582 | — | 5/27/2026 |
| Morgan Stanley | 14,145,735 | $1,672,167,948 | -8.5% | 5/15/2026 |
| State Street | 19,667,723 | $1,413,322,575 | 1.8% | 8/7/2026 |
| Morgan Stanley | 8,878,849 | $638,034,469 | -37.2% | 8/13/2026 |
| Goldman Sachs | 3,863,885 | $456,749,822 | 8.1% | 5/15/2026 |
| Goldman Sachs | 3,574,124 | $449,696,234 | — | 3/25/2026 |
| JP Morgan Chase | 3,407,174 | $396,356,778 | 41.9% | 5/13/2026 |
| Citadel Advisors | 5,210,963 | $374,459,801 | 427.3% | 8/14/2026 |
| JP Morgan Chase | 2,401,497 | $302,156,524 | — | 2/11/2026 |
| Goldman Sachs | 3,736,099 | $268,476,095 | -3.3% | 8/14/2026 |
| Millennium Management | 1,801,255 | $212,926,354 | 329.6% | 5/15/2026 |
| Citadel Advisors | 1,622,005 | $204,080,669 | — | 2/17/2026 |
| JP Morgan Chase | 2,630,925 | $192,715,359 | -22.8% | 8/12/2026 |